Andere talen Acasti Pharma Inc.

Aandelen

ACST

CA00430K8656

Vertraagde tijd Nasdaq Andere beurzen 17:57:12 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,965 ^USD	+4,03%		+1,25%	+2,60%

12/02	Acasti Pharma Inc. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 31 december 2023	CI
07/02	ACASTI PHARMA INC. : Craig-Hallum herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	12/02
Acasti: Fiscal Q3 Earnings Snapshot	12/02
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial	01/02
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	01/02
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	08/01
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	13/12
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	14/11
Acasti: Fiscal Q2 Earnings Snapshot	13/11
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights	13/11
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	13/11
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	24-10-23
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc	24-10-23
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial	23-10-23
Acasti Pharma Inc. Announces Board Changes	11-10-23
Acasti Pharma to Host KOL Event on GTX-104, A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage	05-10-23
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)	04-10-23
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing	28-09-23
Acasti Announces $7.5 Million Private Placement Equity Financing	26-09-23
Acasti Pharma Inc. announced that it has received $7.499388 million in funding from SS Pharma LLC, Shore Pharma LLC	25-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Acasti Pharma Inc.

Aandelen

ACST

CA00430K8656

Andere talen

Filters